首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Clinical cancer research

缩写:CLIN CANCER RES

ISSN:1078-0432

e-ISSN:1557-3265

IF/分区:10.9/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引11950条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Patrick C Lee,Michael T Schweizer,Rosa Nadal Patrick C Lee
P-PSMA-101 is a first-in-class, stem cell memory T cell-enriched, PSMA-targeting CAR-T therapy. This cellular therapy showed notable clinical activity in two patients; however, PSA50 responses were generally modest. While severe immune effe...
Eric Deutsch,Antonin Levy,Laurence Zitvogel Eric Deutsch
Low-dose intestinal irradiation challenges the long-standing view of the gut as a radiation-sensitive organ to avoid. Clinical and mechanistic data suggest that targeted exposure of the small intestine within a 1 to 3 Gy window can remodel ...
Attaya Suvannasankha,Mengying Li,Omonefe Omofuma et al. Attaya Suvannasankha et al.
Purpose: This study aims to compare the risk of second primary malignancy (SPM) between patients with multiple myeloma (MM) who received CAR T therapy versus other systemic anticancer therapies (SACTs). ...
Renyta Moses,Jacquelyn Powers,Alison S Levine et al. Renyta Moses et al.
In individuals with classic Li Fraumeni Syndrome (LFS) due to a loss of function pathogenic germline variant in TP53, loss of p53 tumor suppressive function leads to a high risk of childhood cancers such as sarcomas, adrenal cortical carcin...
Lea Ruge,Felix John,Malte Verheyen et al. Lea Ruge et al.
Introduction: KRAS Q61 mutations represent a heterogeneous molecular subgroup and account for 1-7% of allKRAS mutations in non-small cell lung cancer (NSCLC). The prognostic value of this cohort and its response to differ...
Cheng Xu,Si-Yang Wang,Man Nie et al. Cheng Xu et al.
Purpose: To evaluate the efficacy and safety of dual immunotherapy blocking T-cell immunoglobulin and mucin-domain containing protein-3 (TIM-3) and programmed cell death protein-1 (PD-1) in recurrent/metastatic nasopharyn...
Patrick Schöffski,Roberta Sanfilippo,Javier Martín-Broto et al. Patrick Schöffski et al.
Purpose: The phase 2/3 Brightline-1 trial (NCT05218499) assessed the MDM2-p53 antagonist brigimadlin versus standard-of-care doxorubicin as first-line treatment for MDM2-amplified, locally advanced/metastatic dedifferenti...
Hui K Gan,Lawrence Cher,Po-Ling Inglis et al. Hui K Gan et al.
Purpose: To undertake a Phase 1 and Biodistribution study of the EphA3 antibody ifabotuzumab, and its zirconium labelled derivative 89Zr-ifabotuzumab, in glioblastoma patients. ...
Jacquelyne J Gaddy,Pamela L Kunz,Raghav Sundar Jacquelyne J Gaddy
This commentary on a cohort study of patients with uncommon DPYD variants resulting in increased toxicities highlights the importance of expanding the current DPYD testing profile, the limitations of current testing, and the critical need t...
Hong Jae Chon,Jeong Heo,Do Young Kim et al. Hong Jae Chon et al.
Purpose: Immunotherapy has significantly improved outcomes in advanced hepatocellular carcinoma (HCC). However, most patients eventually progress, and second-line options remain limited. Fostrox, a liver targeted prodrug,...